TRDA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 7.59%

Insider Buying (Last 12 Months): $151,226.80

Insider Selling (Last 12 Months): $906,100.84

Entrada Therapeutics Insider Trading History Chart

Entrada Therapeutics Share Price & Price History

^$17.77

▲ +0.32 (1.83%)

As of 11/19/2024 01:00 AM ET

Days: 30 | 90 | 365

Trump won. Buy this coin now.

From Weiss Ratings | Ad

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.

Entrada Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/13/2024	Natarajan Sethuraman	Insider	Sell	2,700	$20.04	$54,108.00	160,888
11/11/2024	Kory James Wentworth	CFO	Sell	8,637	$19.98	$172,567.26	73,849
11/11/2024	Natarajan Sethuraman	Insider	Sell	1,409	$20.01	$28,194.09	163,588
10/16/2024	Natarajan Sethuraman	Insider	Sell	600	$18.00	$10,800.00	183,216
9/26/2024	Nathan J Dowden	COO	Sell	847	$16.00	$13,552.00	125,149
9/9/2024	Kory James Wentworth	CFO	Sell	3,195	$14.97	$47,829.15	76,486
9/9/2024	Natarajan Sethuraman	Insider	Sell	2,642	$15.09	$39,867.78	183,816
9/9/2024	Nathan J Dowden	COO	Sell	1,904	$15.07	$28,693.28	125,996
9/6/2024	Natarajan Sethuraman	Insider	Sell	600	$15.24	$9,144.00	186,458
9/6/2024	Nathan J Dowden	COO	Sell	399	$15.19	$6,060.81	127,900
7/15/2024	Dipal Doshi	CEO	Sell	1,600	$17.81	$28,496.00	334,475
7/15/2024	Natarajan Sethuraman	Insider	Sell	638	$18.00	$11,484.00	188,814
7/12/2024	Dipal Doshi	CEO	Sell	300	$18.00	$5,400.00	336,075
7/12/2024	Natarajan Sethuraman	Insider	Sell	600	$18.00	$10,800.00	189,452
7/8/2024	Kory James Wentworth	CFO	Sell	1,758	$14.95	$26,282.10	81,412
6/13/2024	Dipal Doshi	CEO	Sell	1,000	$16.17	$16,170.00	336,375
5/20/2024	Natarajan Sethuraman	Insider	Sell	9,675	$15.19	$146,963.25	190,052
5/16/2024	Dipal Doshi	CEO	Sell	1,800	$15.00	$27,000.00	338,575
5/16/2024	Natarajan Sethuraman	Insider	Sell	1,000	$15.00	$15,000.00	208,032
5/8/2024	Peter S Kim	Director	Buy	2,276	$14.04	$31,955.04	65,212
4/8/2024	Peter S Kim	Director	Buy	2,600	$13.57	$35,282.00	62,936
3/28/2024	Peter S Kim	Director	Buy	1,512	$13.75	$20,790.00	60,336
3/25/2024	Peter S Kim	Director	Buy	3,180	$13.36	$42,484.80	56,074
3/21/2024	Peter S Kim	Director	Buy	704	$13.24	$9,320.96	49,776
3/19/2024	Peter S Kim	Director	Buy	900	$12.66	$11,394.00	47,944
2/15/2024	Dipal Doshi	CEO	Sell	1,000	$15.00	$15,000.00	243,279
1/16/2024	Dipal Doshi	CEO	Sell	1,000	$15.99	$15,990.00	244,279
12/26/2023	Kory James Wentworth	CFO	Sell	94	$16.67	$1,566.98	49,571
12/22/2023	Kory James Wentworth	CFO	Sell	10,206	$15.69	$160,132.14	49,571
12/20/2023	Dipal Doshi	CEO	Sell	1,000	$15.00	$15,000.00	245,279
11/13/2023	Dipal Doshi	CEO	Sell	1,000	$16.23	$16,230.00	246,279
10/17/2023	Dipal Doshi	CEO	Sell	1,000	$15.00	$15,000.00	247,279
9/13/2023	Dipal Doshi	CEO	Sell	1,000	$15.00	$15,000.00	248,279
9/6/2023	Kory James Wentworth	CFO	Sell	950	$13.48	$12,806.00	49,571
9/6/2023	Nathan J Dowden	COO	Sell	972	$13.47	$13,092.84	48,168
9/6/2023	Nerissa Kreher	Insider	Sell	892	$13.48	$12,024.16	40,037
8/14/2023	Dipal Doshi	CEO	Sell	1,000	$15.67	$15,670.00	201,069
8/4/2023	Nerissa Kreher	Insider	Sell	6,898	$14.14	$97,537.72	27,130
8/2/2023	Nerissa Kreher	Insider	Sell	10,348	$15.19	$157,186.12	27,130
7/11/2023	Kory James Wentworth	CFO	Sell	3,884	$18.00	$69,912.00	36,747
7/10/2023	Natarajan Sethuraman	Insider	Sell	3,026	$18.00	$54,468.00	168,299
7/10/2023	Nathan J Dowden	COO	Sell	3,200	$18.00	$57,600.00	39,273
6/22/2023	Nathan J Dowden	COO	Sell	7,097	$16.02	$113,693.94	42,473
6/21/2023	Kory James Wentworth	CFO	Sell	17,500	$15.01	$262,675.00	27,957
6/20/2023	Nathan J Dowden	COO	Sell	8,885	$14.94	$132,741.90	49,570
4/27/2023	Dipal Doshi	CEO	Sell	2,000	$13.71	$27,420.00	202,069
4/17/2023	Dipal Doshi	CEO	Sell	2,092	$18.01	$37,676.92	204,069
4/17/2023	Natarajan Sethuraman	Insider	Sell	3,961	$18.00	$71,298.00	171,325
3/27/2023	Dipal Doshi	CEO	Sell	2,000	$14.72	$29,440.00	255,811
1/27/2023	Dipal Doshi	CEO	Sell	2,000	$12.00	$24,000.00	163,835
1/9/2023	Dipal Doshi	CEO	Sell	2,410	$15.02	$36,198.20	165,835
12/29/2022	Dipal Doshi	CEO	Sell	400	$15.01	$6,004.00	168,245
12/27/2022	Dipal Doshi	CEO	Sell	9,669	$15.02	$145,228.38	173,166
12/8/2022	Kory James Wentworth	CFO	Sell	4,550	$18.95	$86,222.50	16,509
12/5/2022	Kory James Wentworth	CFO	Sell	200	$18.05	$3,610.00	16,509
12/2/2022	Kory James Wentworth	CFO	Sell	2,910	$18.20	$52,962.00	16,509
11/28/2022	Dipal Doshi	CEO	Sell	2,000	$13.91	$27,820.00	182,835
10/31/2022	Nathan J Dowden	COO	Sell	2,100	$24.05	$50,505.00	45,283
10/27/2022	Dipal Doshi	CEO	Sell	2,000	$21.66	$43,320.00	184,835
10/25/2022	Nerissa Kreher	Insider	Sell	8,040	$20.88	$167,875.20	20,716
10/24/2022	Dipal Doshi	CEO	Sell	2,342	$19.30	$45,200.60	198,896
10/24/2022	Nathan J Dowden	COO	Sell	2,404	$19.30	$46,397.20	56,731
10/20/2022	Dipal Doshi	CEO	Sell	811	$18.01	$14,606.11	204,024
10/20/2022	Nathan J Dowden	COO	Sell	905	$18.07	$16,353.35	61,906
9/28/2022	Dipal Doshi	CEO	Sell	3,085	$15.23	$46,984.55	204,835
9/28/2022	Nerissa Kreher	Insider	Sell	3,122	$15.25	$47,610.50	20,716
9/26/2022	Dipal Doshi	CEO	Sell	3,083	$15.32	$47,231.56	212,339
9/26/2022	Nathan J Dowden	COO	Sell	1,544	$15.45	$23,854.80	62,811
9/26/2022	Nerissa Kreher	Insider	Sell	3,068	$15.33	$47,032.44	20,716
9/23/2022	Dipal Doshi	CEO	Sell	1,023	$15.07	$15,416.61	215,422
9/23/2022	Nathan J Dowden	COO	Sell	1,018	$15.07	$15,341.26	64,355
9/23/2022	Nerissa Kreher	Insider	Sell	939	$15.09	$14,169.51	20,716
9/21/2022	Dipal Doshi	CEO	Sell	3,402	$15.12	$51,438.24	216,445
9/21/2022	Nathan J Dowden	COO	Sell	3,275	$15.13	$49,550.75	65,373
9/21/2022	Nerissa Kreher	Insider	Sell	3,341	$15.08	$50,382.28	20,716
9/15/2022	Dipal Doshi	CEO	Sell	200	$15.04	$3,008.00	219,847
9/15/2022	Nathan J Dowden	COO	Sell	100	$15.01	$1,501.00	68,648
9/15/2022	Nerissa Kreher	Insider	Sell	106	$15.01	$1,591.06	20,716
9/9/2022	Nerissa Kreher	Insider	Sell	800	$15.07	$12,056.00	20,716
9/8/2022	Dipal Doshi	CEO	Sell	1,100	$15.16	$16,676.00	220,735
9/8/2022	Nathan J Dowden	COO	Sell	912	$15.15	$13,816.80	69,613
8/31/2022	Dipal Doshi	CEO	Sell	171	$12.00	$2,052.00	206,710
8/29/2022	Dipal Doshi	CEO	Sell	1,639	$12.88	$21,110.32	207,071
8/25/2022	Kory James Wentworth	CFO	Sell	1,551	$14.18	$21,993.18	10,986
8/23/2022	Kory James Wentworth	CFO	Sell	2,909	$13.09	$38,078.81	14,538
8/18/2022	Kory James Wentworth	CFO	Sell	200	$13.00	$2,600.00	20,221
8/16/2022	Kory James Wentworth	CFO	Sell	200	$13.00	$2,600.00	20,441
7/27/2022	Dipal Doshi	CEO	Sell	2,000	$12.00	$24,000.00	208,710
6/27/2022	Dipal Doshi	CEO	Sell	4,000	$12.00	$48,000.00	210,710
6/27/2022	Nathan J Dowden	COO	Sell	7,714	$13.00	$100,282.00	64,893
6/6/2022	Bros. Advisors Lp Baker	Major Shareholder	Buy	38,304	$6.41	$245,528.64	4,501,658
6/2/2022	Bros. Advisors Lp Baker	Major Shareholder	Buy	2,643	$5.82	$15,382.26	4,467,393
5/23/2022	Bros. Advisors Lp Baker	Major Shareholder	Buy	7,837	$5.99	$46,943.63	4,443,719
5/20/2022	Bros. Advisors Lp Baker	Major Shareholder	Buy	16,849	$5.84	$98,398.16	4,436,709
5/18/2022	Bros. Advisors Lp Baker	Major Shareholder	Buy	34,433	$6.00	$206,598.00	4,421,689
5/16/2022	Bros. Advisors Lp Baker	Major Shareholder	Buy	19,000	$5.83	$110,770.00	4,374,493
1/12/2022	John F. Crowley	Director	Buy	5,000	$9.71	$48,550.00

This company will win the AI race

From Porter & Company | Ad

Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

SEC Filings (Institutional Ownership Changes) for Entrada Therapeutics (NASDAQ:TRDA)

86.39% of Entrada Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Entrada Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/19/2024	Barclays PLC	45,110	$0.72M	0.0%	+210.6%	0.121%
11/16/2024	Geode Capital Management LLC	576,451	$9.21M	0.0%	+8.8%	1.540%
11/15/2024	Barclays PLC	45,110	$0.72M	0.0%	+210.6%	0.121%
11/15/2024	Public Employees Retirement System of Ohio	16,259	$0.26M	0.0%	+89.1%	0.043%
11/15/2024	XTX Topco Ltd	39,670	$0.63M	0.0%	N/A	0.106%
11/15/2024	Jane Street Group LLC	15,514	$0.25M	0.0%	-42.0%	0.041%
11/15/2024	Wellington Management Group LLP	1,029,369	$16.45M	0.0%	-0.4%	2.751%
11/15/2024	State Street Corp	469,601	$7.50M	0.0%	+5.5%	1.255%
11/15/2024	Jacobs Levy Equity Management Inc.	201,803	$3.23M	0.0%	+50.3%	0.539%
11/15/2024	Janus Henderson Group PLC	1,711,459	$27.36M	0.0%	+10.5%	4.574%
11/14/2024	Martingale Asset Management L P	37,923	$0.61M	0.0%	+36.9%	0.101%
11/14/2024	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	14,156	$0.23M	0.0%	+34.7%	0.038%
11/13/2024	FMR LLC	1,743,498	$27.86M	0.0%	-4.7%	4.659%
11/12/2024	Charles Schwab Investment Management Inc.	185,984	$2.97M	0.0%	+14.6%	0.497%
11/12/2024	Massachusetts Financial Services Co. MA	69,394	$1.11M	0.0%	N/A	0.185%
11/8/2024	Connor Clark & Lunn Investment Management Ltd.	138,605	$2.22M	0.0%	+132.4%	0.370%
11/5/2024	GSA Capital Partners LLP	36,577	$0.59M	0.0%	+71.8%	0.098%
11/4/2024	Los Angeles Capital Management LLC	33,932	$0.54M	0.0%	N/A	0.091%
10/28/2024	US Bancorp DE	2,658	$42K	0.0%	N/A	0.007%
10/23/2024	BayBridge Capital Group LLC	29,039	$0.46M	0.3%	N/A	0.086%
10/19/2024	Allspring Global Investments Holdings LLC	20,521	$0.33M	0.0%	-25.7%	0.055%
10/3/2024	SG Americas Securities LLC	9,745	$0.16M	0.0%	N/A	0.026%
8/15/2024	The Manufacturers Life Insurance Company	57,098	$0.81M	0.0%	+3.9%	0.169%
8/14/2024	Squarepoint Ops LLC	25,950	$0.37M	0.0%	-23.9%	0.077%
8/14/2024	Marshall Wace LLP	65,943	$0.94M	0.0%	+27.5%	0.195%
8/9/2024	Renaissance Technologies LLC	44,600	$0.64M	0.0%	N/A	0.132%
8/8/2024	American Century Companies Inc.	384,973	$5.49M	0.0%	+5.1%	1.140%
8/6/2024	Acadian Asset Management LLC	13,367	$0.19M	0.0%	+135.1%	0.040%
8/1/2024	Rhumbline Advisers	36,940	$0.53M	0.0%	+25.3%	0.109%
7/26/2024	Allspring Global Investments Holdings LLC	27,631	$0.39M	0.0%	+87.2%	0.082%
7/26/2024	Bank of New York Mellon Corp	125,436	$1.79M	0.0%	+13.4%	0.372%
5/16/2024	California State Teachers Retirement System	12,631	$0.18M	0.0%	-11.1%	0.037%
5/15/2024	Price T Rowe Associates Inc. MD	2,753,357	$39.02M	0.0%	-8.5%	8.156%
5/10/2024	Acadian Asset Management LLC	5,685	$79K	0.0%	N/A	0.017%
5/10/2024	Vanguard Group Inc.	1,078,908	$15.29M	0.0%	+1.3%	3.203%
5/7/2024	SG Americas Securities LLC	7,687	$0.11M	0.0%	-34.4%	0.023%
4/30/2024	Allspring Global Investments Holdings LLC	14,763	$0.21M	0.0%	+427.6%	0.044%
4/25/2024	New York State Teachers Retirement System	1,915	$27K	0.0%	N/A	0.006%
4/18/2024	Allspring Global Investments Holdings LLC	14,763	$0.21M	0.0%	+427.6%	0.044%
3/5/2024	Wellington Management Group LLP	1,047,780	$15.81M	0.0%	+0.2%	3.140%
2/14/2024	72 Investment Holdings LLC	172,600	$2.61M	11.6%	-66.1%	0.517%
2/13/2024	Tower Research Capital LLC TRC	5,780	$87K	0.0%	+476.3%	0.017%
2/6/2024	Swiss National Bank	23,000	$0.35M	0.0%	-8.7%	0.069%
1/30/2024	Strs Ohio	24,100	$0.36M	0.0%	+792.6%	0.072%
1/12/2024	SG Americas Securities LLC	11,714	$0.18M	0.0%	+27.7%	0.035%
12/1/2023	Wellington Management Group LLP	1,045,652	$16.52M	0.0%	+2.6%	3.134%
11/15/2023	Redmile Group LLC	1,284,000	$20.29M	1.0%	-2.1%	3.848%
11/14/2023	Corton Capital Inc.	10,485	$0.17M	0.1%	-42.0%	0.031%
10/27/2023	Allspring Global Investments Holdings LLC	2,798	$44K	0.0%	N/A	0.008%
10/27/2023	TD Asset Management Inc	119,254	$1.88M	0.0%	+100.0%	0.359%
10/13/2023	SG Americas Securities LLC	9,174	$0.15M	0.0%	N/A	0.028%
9/21/2023	Barclays PLC	6,440	$97K	0.0%	-37.0%	0.019%
8/11/2023	Nan Fung Group Holdings Ltd	49,082	$0.74M	0.5%	-33.3%	0.148%
8/4/2023	American International Group Inc.	10,299	$0.16M	0.0%	N/A	0.031%
7/31/2023	Strs Ohio	2,700	$40K	0.0%	N/A	0.008%
5/11/2023	CHI Advisors LLC	56,374	$0.82M	0.2%	N/A	0.170%
5/9/2023	Y Intercept Hong Kong Ltd	10,188	$0.15M	0.0%	N/A	0.031%
2/14/2023	683 Capital Management LLC	10,355	$0.14M	0.0%	N/A	0.033%
2/9/2023	Citigroup Inc.	51,042	$0.69M	0.0%	+3,124.4%	0.163%
2/8/2023	Swiss National Bank	26,500	$0.36M	0.0%	N/A	0.084%
11/15/2022	TCG Crossover Management LLC	642,189	$10.12M	3.0%	-3.2%	2.045%
11/15/2022	Laurion Capital Management LP	199,066	$3.14M	0.0%	+54.2%	0.634%
11/10/2022	Nan Fung Group Holdings Ltd	141,593	$2.23M	1.4%	-18.4%	0.451%
11/7/2022	TD Asset Management Inc.	59,496	$0.93M	0.0%	+3.2%	0.189%
8/15/2022	Laurion Capital Management LP	129,066	$1.57M	0.0%	N/A	0.411%
5/27/2022	Walleye Capital LLC	44,652	$0.42M	0.0%	N/A	0.142%
5/5/2022	New York State Common Retirement Fund	4,880	$46K	0.0%	N/A	0.016%
2/18/2022	TCG Crossover Management LLC	663,694	$11.36M	5.3%	N/A	2.126%
2/14/2022	Redmile Group LLC	1,954,420	$33.46M	0.8%	N/A	6.262%
2/14/2022	72 Investment Holdings LLC	509,024	$8.71M	7.7%	N/A	1.631%
2/14/2022	Suvretta Capital Management LLC	106,000	$1.82M	0.0%	N/A	0.340%
2/14/2022	Ghisallo Capital Management LLC	15,000	$0.26M	0.0%	N/A	0.048%
2/14/2022	Goldman Sachs Group Inc.	7,626,182	$130.56M	0.0%	N/A	24.433%
2/11/2022	MPM Asset Management LLC	4,425,784	$75.77M	16.4%	N/A	14.179%
2/10/2022	TD Asset Management Inc.	57,675	$0.99M	0.0%	N/A	0.185%
2/8/2022	Northern Trust Corp	79,483	$1.36M	0.0%	N/A	0.255%
2/3/2022	5AM Venture Management LLC	4,408,379	$75.47M	14.2%	N/A	14.124%

Data available starting January 2016

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $17.77

$17.09

$17.83

50 Day Range

MA: $16.80

$13.65

$19.96

52 Week Range

Now: $17.77

$10.75

$20.49

Volume

75,358 shs

Average Volume

107,386 shs

Market Capitalization

$664.95 million

P/E Ratio

11.18

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Entrada Therapeutics?: Entrada Therapeutics' top insider shareholders include:
Dipal Doshi (CEO)
Natarajan Sethuraman (Insider)
Nathan J Dowden (COO)
Kory James Wentworth (CFO)
Peter S Kim (Director)
Nerissa Kreher (Insider)
Learn More about top insider investors at Entrada Therapeutics.
Who are the major institutional investors of Entrada Therapeutics?: Entrada Therapeutics' top institutional shareholders include:
FMR LLC — 4.66%
Janus Henderson Group PLC — 4.57%
Wellington Management Group LLP — 2.75%
Geode Capital Management LLC — 1.54%
State Street Corp — 1.25%
Jacobs Levy Equity Management Inc. — 0.54%
Learn More about top institutional investors of Entrada Therapeutics stock.
Which institutional investors are selling Entrada Therapeutics stock?: Within the last quarter, TRDA stock was sold by these institutional investors:
FMR LLC
Jane Street Group LLC
Allspring Global Investments Holdings LLC
Wellington Management Group LLP
Within the last year, company insiders that have sold Entrada Therapeutics company stock include:
Dipal Doshi (CEO)
Natarajan Sethuraman (Insider)
Nathan J Dowden (COO)
Kory James Wentworth (CFO)
Learn More investors selling Entrada Therapeutics stock.
Which institutional investors are buying Entrada Therapeutics stock?: In the previous quarter, TRDA stock was bought by institutional investors including:
Janus Henderson Group PLC
Connor Clark & Lunn Investment Management Ltd.
Massachusetts Financial Services Co. MA
Jacobs Levy Equity Management Inc.
Geode Capital Management LLC
XTX Topco Ltd
Los Angeles Capital Management LLC
Barclays PLC